UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 10, 2015
 
CORD BLOOD AMERICA, INC.
 (Exact name of registrant as specified in its charter)
 
Florida
  
000-50746
  
90-0613888
(State or Other Jurisdiction of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

1857 Helm Drive, Las Vegas, NV 89119
 (Address of Principal Executive Office) (Zip Code)

(702) 914-7250
 (Registrant’s telephone number, including area code)
_______________________________
 
Copies to:
Joseph R. Vicente
1857 Helm Drive, Las Vegas, NV 89119
Phone: (702) 914-7250
Fax: (702) 914-7251
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 8.01
 
On December 10, 2015, Cord Blood America, Inc. (the “Company”) issued a press release announcing that the Company will undertake a review of strategic alternatives, which may include a possible sale of assets or the sale of the Company, along with other alternatives or forms of business combination.  The press release further announced that the review of strategic alternatives will be run by a committee of the Board of Directors consisting of all independent directors.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
 
Forward-Looking Statements

Some statements made in this filing are forward-looking statements. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Statements made herein are as of the date of this filing and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Item 9.01    Financial Statements and Exhibits

(d) Exhibits
 
Exhibit No.   Description
     
 
Press Release dated December 10, 2015
 
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
CORD BLOOD AMERICA, INC.
  
 
(Registrant)
  
       
Date: December 10, 2015
By:
/s/ Joseph Vicente  
    President  
       
       
 
 

3
 


Exhibit 99.1
 
 
 
 
CBAI Announces Review of Strategic Alternatives
 
LAS VEGAS, NV / ACCESSWIRE / December 10, 2015 / Cord Blood America, Inc. (www.cordblood-america.com) (OTC: CBAI) ("CBAI" or the "Company") today announced that its Board of Directors (the “Board”) has unanimously determined to undertake a review of strategic alternatives available to the Company, which may include a possible sale of assets or the sale of the Company, along with other alternatives or forms of business combination. The review of any alternatives would be evaluated against the Company's progress as a standalone business as it continues to execute or considers a change in its strategic business plan.
 
Stated CBAI’s Chairman, David Sandberg, "Our Board is committed to acting in the best interests of shareholders and believes it is appropriate to explore strategic alternatives that might provide additional opportunities to enhance value for shareholders."
 
The Company noted that no decision has been made to enter into any transaction at this time, and there can be no assurance that the Board's review process will result in any transaction or other alternative. The review of strategic alternatives will be run by a committee of the Board consisting of all independent directors. There is no set timetable for the strategic review process and the Company does not intend to provide updates unless or until the Board approves a specific action or otherwise determines that disclosure is appropriate or necessary.
 
About Cord Blood America, Inc.
 
Cord Blood America, Inc. is the parent company of CorCell Companies, Inc. which, along with Cord Blood America, Inc., facilitates umbilical cord blood and cord tissue stem cell processing and storage for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life- saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor information and http://www.corcell.com/ for customer information.
 
Forward-Looking Statements
 
Some statements made in this press release are forward-looking statements. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
 
Contact:
 
Anthony Snow
asnow@cordblood-america.com
 
SOURCE: Cord Blood America, Inc.